Single-center, prospective, and observational study on the management and treatment of impetigo in a pediatric population.
Eur Rev Med Pharmacol Sci
; 27(19): 9273-9278, 2023 Oct.
Article
in En
| MEDLINE
| ID: mdl-37843341
ABSTRACT
OBJECTIVE:
Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo. PATIENTS ANDMETHODS:
This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated.RESULTS:
A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%.CONCLUSIONS:
Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin's clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Impetigo
Limits:
Child
/
Humans
Language:
En
Journal:
Eur Rev Med Pharmacol Sci
Year:
2023
Document type:
Article